Lates News

According to AI fast news, Huayuan Securities released a research report on April 3 giving a "buy" rating to Bioasis Technologies (688796.SH). The rating reasons mainly include: 1) Bioasis Technologies is an international biotechnology company driven by innovative technology for new drug research and development, dedicated to providing high-quality products and services in the field of new drug research and development; 2) The "Thousand Mice, Ten Thousand Antigens" plan is comprehensively upgraded, with AI and automation platforms empowering early research and development; 3) Preclinical products and services business maintains high growth, innovative animal models build core barriers. (Daily Economic News)